COVID-19 and Diabetes: The Importance of Controlling RAGE.

Keywords: COVID-19; diabetes; RAGE (receptor for advanced glycation end products); HMGB-1 (high mobility group box 1); pneumonia; coagulation disorders EN COVID-19 diabetes RAGE (receptor for advanced glycation end products) HMGB-1 (high mobility group box 1) pneumonia coagulation disorders 1 6 6 07/20/20 20200714 NES 200714 Introduction The recent looming pandemic of Coronavirus disease 2019 (COVID-19) is caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has 80% homology with SARS-CoV-1 and 50% homology with the Middle East respiratory syndrome (MERS) viruses, both pathogens most likely originating from bats ([1]). Rage and its Ligands As Key Regulators of The Innate Immunity and Inflammation and Their Role... RAGE has been named for its ability to bind advanced glycation end products (AGEs) that are found at increased levels in patients with hyperglycemia and contribute to chronic vascular complications of DM patients ([16]). An encouragement to chase this track more in depth comes from the observation that in non-COVID-19 critically ill hyperglycemic patients admitted at ICU, plasma levels of sRAGE are higher in DM vs. non-DM patients, and reduced by intensive insulin therapy only in DM patients ([41]). [Extracted from the article]